Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 31 of 67 for:    stem cell peripheral arterial disease AND Occlusive

Administration of Adipose-derived Stem Cells (ASC) in Patient With Critical Limb Ischemia (ACellDREAM2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03968198
Recruitment Status : Not yet recruiting
First Posted : May 30, 2019
Last Update Posted : August 26, 2019
Sponsor:
Collaborators:
Institut National de la Santé Et de la Recherche Médicale, France
Etablissement Français du Sang
Information provided by (Responsible Party):
University Hospital, Toulouse

Brief Summary:

Different types of stem cells have recently been studied in clinical trial on ischemic disease of the heart and muscular arteries. Adipose derived stem cell, have shown in vitro and in vivo models a stronger potential of success in recovering from ischemic disease and oxygenation of the tissues. The investigators already shown in a phase I study, that adipose derived mesenchymal cells injected in patients with critical limb ischemia and no option for revascularization, had a very good tolerance and interesting effects on skin oxygenation and healing.

The aim of the present clinical trial is to confirm the efficacy autologous transplantation of adipose tissue derived mesenchymal cells in patients with critical limb ischemia with poor options or no option for revascularization.


Condition or disease Intervention/treatment Phase
Critical Limb Ischemia and Peripheral Artery Disease Drug: Autologous ASC (for Adipose-derived Stem/Stroma Cell) Phase 2

Detailed Description:

Lower limbs arteries are a frequent localization of atheroma in elderly people (15-20% after 70 years). The most severe stage of the disease, critical limb ischemia (CLI), defined clinically by the presence of rest pain or ischemic ulcer, has a dramatic prognosis at 12 months, with 30% of the patients alive with an amputation, 20% mortality and only 20% of patients with a resolved disease, independently from the treatment. The only validated treatment for this disease is revascularization by endovascular procedures or open surgery. Patients with no option or poor option (high risk) for revascularization have the worst prognosis.

Current research is focusing on the development of cell-based therapies using different sources of stem cells which can provide revascularization and oxygenation of the tissues. A specific form of stem cells, called Adipose-derived Stem/Stroma Cells (ASC), has shown promise for recovering from ischemic disease like critical limb ischemia (CLI) in preclinical trial and trial in phase I. This study will confirm the efficacy autologous transplantation of adipose tissue derived mesenchymal cells in patients with critical limb ischemia with poor options or no option for revascularization.

This study is a phase II, prospective, multicentric, open trial and no comparative. A maximum of 43 patients will be included in two-stage to receive 90*106 intramuscular injection of ASC. Patients will be followed-up for 6 months.

The primary endpoint is the number of patients alive without major amputation and without critical limb ischemia (defined as the presence of rest pain or ischemic ulcer and ankle pressures less than 70 mmHg or toe systolic pressure less than 50 mmHg or TcPO2 of less than 30 mmHg, at six month).

The secondary endpoints are to evaluate:

  • the number of new vessels in the treated limb by standardized angiographic magnetic resonance
  • the blood flow by laser Doppler, transcutaneous pressure of oxygen (TcPO2), ankle pressure
  • the percentage reduction of wound surface and percentage of complete ulcer healing
  • the pain reduction by standardized evaluation (visual scale and drug consumption)
  • the percentage of wound infection and irritative dermatitis (expected adverse events)
  • interleukin-1, interleukin-2, interleukin-4, interleukin-6, interleukin-10, interleukin-12, Tumor Necrosis Factor alpha (TNFα)measurements in blood samples
  • Mesenchymal stem cells MSC trophic factors and immune- modulators (Hepatocyte growth factor (HGF), Vascular Endothelial Growth Factor (VEGF), indoleamine 2, 3-dioxygenase (IDO), Human Leucocyte Antigen G (HLA-G)) in vitro.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 43 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Autologous Transplantation of Adipose Tissue Derived Mesenchymal Stroma/Stem Cells (ASC) in Patients With Critical Limb Ischemia
Estimated Study Start Date : October 2019
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : July 2021

Arm Intervention/treatment
Experimental: ASC (Adipose-derived Stem/Stroma Cells)
Patients administrated with autologous ASC in their ischemic inferiors limbs
Drug: Autologous ASC (for Adipose-derived Stem/Stroma Cell)
After adipose tissue aspiration (liposuction) by an authorized person, ASCs were isolated and cultured during 14±2 days by the French Blood Establishment. Then, patients receive intramuscular injections of ASCs.




Primary Outcome Measures :
  1. Number of patients alive without major amputation [ Time Frame: Between 1 and 6 months ]
    Evaluation of the presence of rest pain or ischemic ulcer and ankle pressures less than 70 mmHg or toe systolic pressure less than 50 mmHg or TcPO2 of less than 30 mmHg, at six month.

  2. Number of patients alive without critical limb ischemia [ Time Frame: Between 1 and 6 months ]
    Evaluation of the presence of rest pain or ischemic ulcer and ankle pressures less than 70 mmHg or toe systolic pressure less than 50 mmHg or TcPO2 of less than 30 mmHg, at six month.


Secondary Outcome Measures :
  1. New vessels [ Time Frame: Between 1 and 6 months ]
    Blind evaluation of the number of new vessels in the treated limb by standardized angiographic magnetic resonance

  2. Blood flow [ Time Frame: Between 1 and 6 months ]
    Evaluation of the blood flow by laser Doppler, transcutaneous pressure of oxygen (TcPO2), ankle pressure.

  3. Wound surface reduction [ Time Frame: Between 1 and 6 months ]
    Percentage reduction of wound surface (standardized layer measurement).

  4. Ulcer healing [ Time Frame: Between 1 and 6 months ]
    Evaluation of percentage of complete ulcer healing.

  5. Pain reduction [ Time Frame: Between 1 and 6 months ]

    Evaluation of pain reduction by standardized evaluation (visual scale and drug consumption).

    The visual scale is in a form of plastic ruler and measures the intensity of pain on a scale ranging from 0 (no pain) to 10 (maximum pain).


  6. Wound infection [ Time Frame: Between 1 and 6 months ]
    Percentage of wound infection and irritative dermatitis (expected adverse events)

  7. Immuno measures in blood sample [ Time Frame: Between 1 and 6 months ]
    interleukin-1, interleukin-2, interleukin-4, interleukin-6, interleukin-10, interleukin-12, Tumor Necrosis Factor alpha (TNFα), will be measured out in blood samples.

  8. Immuno measures in vitro [ Time Frame: Between 1 and 6 months ]
    Mesenchymal stem cells (MSC) trophic factors and immune- modulators (Hepatocyte growth factor (HGF), Vascular Endothelial Growth Factor (VEGF), indoleamine 2, 3-dioxygenase (IDO), Human Leucocyte Antigen G (HLA-G)) will be studied in vitro.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients over 18 years old,
  • Rest pain or ischemic ulcers /gangrene of the lower limb, present for at least 15 days, requiring analgesic absorption, with ankle pressures less than 70 mmHg or toe systolic pressure less than 50 mmHg or TcPO2 of less than 30 mmHg

Patient with persistent CLI after revascularization will be included if :

  1. they have severe cardiac, respiratory or renal disease who are at increased risk of complication from surgery or anesthesia, e.g. moderately severe or severe heart failure (NYHA class III or IV), severe or very severe Chronic Obstructive Pulmonary disease or severe renal disease (creatinine clearance <30 mL/minute).

    OR

  2. there is no option for endovascular or open surgery revascularization ; or poor option (defined by: need for an infra-popliteal by-pass without the availability of autologous great saphenous vein, need for use of great saphenous vein <3 mm in diameter for tibial level bypass based on venous duplex ultrasound, or calcified or small (<2 mm) distal target vessel, or open wound on the receiving site or infrapopliteal PAD)

    • Patients who signed the informed consent,
    • Patient affiliated to a social security system

Exclusion Criteria:

  • History of cancer
  • Need of a major amputation (amputation at or above the ankle) within 2 weeks,
  • Ulcers with exposure of tendons, osteomyelitis, or clinically uncontrolled infection,
  • TcPO2 <10 mmHg at rest and < 30 mmHg sitting with legs dependent (very poor vascular reserve),
  • Patient under judicial protection,
  • Pregnant women,
  • Women of childbearing age without effective contraception.
  • Refusal of the patient to participate in the study,
  • Positive HIV-1 or 2, Human T Leukemia virus (HTLV)-1 or 2, Hepatite B Virus (HBV) (except vaccine profile), Syphilis (except inactive disease), or Hepatite C Virus (HCV)
  • Patients necessitating drugs with inhibitory or stimulatory effect on the growth and multiplication of cells or drugs with immunosuppressive effect: Cyclosporine, Mycophenolate mofetil, Azathioprine, Tacrolimus (systemic), Anthracyclines, Neupogen or equivalent, Etanercept, Interferons, Corticoids at anti-inflammatory doses.
  • No possibility of adipose tissue harvest and cell injection in the leg
  • Another clinical trial participation (except non interventional studies),
  • Patient under judicial protection,
  • Pregnant and breastfeeding women,
  • Women of childbearing age without effective contraception,
  • Lack in understanding the nature and aims of the study and/or difficulties in communication with the investigator.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03968198


Contacts
Layout table for location contacts
Contact: BURA-RIVIERE Alessandra, PhD +33-5 61 32 24 38 ext 33 bura-riviere.a@chu-toulouse.fr

Locations
Layout table for location information
France
CHU de BORDEAUX Not yet recruiting
Bordeaux, France, 33000
Contact: Joël CONSTANS, Pr    05 56 79 58 16    Joel.constans@chu-bordeaux.fr   
CHU de LIMOGES Not yet recruiting
Limoges, France, 87000
Contact: Philippe LACROIX, Pr    05 55 05 63 82    philippe.lacroix@unilim.fr   
Rangueil Hospital Not yet recruiting
Toulouse, France, 31059
Contact: BURA-RIVIERE Alessandra, PhD    05 61 32 24 38 ext 33    bura-riviere.a@chu-toulouse.fr   
Sponsors and Collaborators
University Hospital, Toulouse
Institut National de la Santé Et de la Recherche Médicale, France
Etablissement Français du Sang
Investigators
Layout table for investigator information
Principal Investigator: BURA-RIVIERE Alessandra, PhD Toulouse University Hospital

Layout table for additonal information
Responsible Party: University Hospital, Toulouse
ClinicalTrials.gov Identifier: NCT03968198     History of Changes
Other Study ID Numbers: 14 7441 01
First Posted: May 30, 2019    Key Record Dates
Last Update Posted: August 26, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University Hospital, Toulouse:
Cell therapy
ASC autologous
CLI
PAD
No option
Additional relevant MeSH terms:
Layout table for MeSH terms
Peripheral Arterial Disease
Ischemia
Pathologic Processes
Atherosclerosis
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Peripheral Vascular Diseases